TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from 4SC AG ( (DE:VSC) ).
4SC AG announced that the European Medicines Agency (EMA) has provided feedback on its marketing authorisation application for resminostat, an orphan medicinal product for treating cutaneous T-cell lymphoma (CTCL). The EMA’s assessment report indicated that the application is currently not approvable due to major objections. 4SC AG plans to evaluate the feedback and determine the best course of action to address the EMA’s concerns within the given one-month response deadline.
More about 4SC AG
4SC AG is a biotechnology company based in Planegg-Martinsried, Germany, and is listed on the Frankfurt Stock Exchange. The company focuses on developing small molecule drugs for cancer and autoimmune diseases, with a particular emphasis on epigenetic and cancer immunotherapy treatments.
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €56.71M
Learn more about VSC stock on TipRanks’ Stock Analysis page.